Recent studies carried out in this laboratory have shown a potentiating effect of estrogen therapy on the biologic acLivity of administered hydrocortisone (1). The glucosuric effect of exogenous hydrocortisone was much greater when ethinyl estradiol (EE) was administered together with the steroid, while a potentiating effect was not clearly demonstrated with a number of 1,2-unsaturated steroids. Estrogen therapy has been shown to increase the plasma levels of 17-hydroxycorticoids (2, 3) owing to an increase in the levels of transcortin (CBG, corticosteroid-binding globulin) (4, 5), but such a change does not occur in urinary corticoids, which may show a decrease (6).
Recent studies carried out in this laboratory have shown a potentiating effect of estrogen therapy on the biologic acLivity of administered hydrocortisone (1) . The glucosuric effect of exogenous hydrocortisone was much greater when ethinyl estradiol (EE) was administered together with the steroid, while a potentiating effect was not clearly demonstrated with a number of 1,2-unsaturated steroids. Estrogen therapy has been shown to increase the plasma levels of 17-hydroxycorticoids (2, 3) owing to an increase in the levels of transcortin (CBG, corticosteroid-binding globulin) (4, 5) , but such a change does not occur in urinary corticoids, which may show a decrease (6) .
In the present study, an attempt was made to determine whether estrogen therapy affects the pituitary-adrenal response in man.
METHODS
Eleven patients were studied in the metabolic ward of the Los Angeles County General Hospital. Table I shows age, sex, diagnosis, and duration of EE treatment. Each subject acted as his own control. Methopyrapone (2-methyl-1,2-bis-[3-pyridyl] -propanone) was given orally to these patients in doses of 500 or 750 mg every 4 hours for 2 days during the control period. The same doses were repeated during EE administration. The response to methcpyrapone was estimated as urinary 17-ketogen-c steroids (17-KGS) by the method of Rutherford and Nelson (7) in 24-hour collections the day before, during, and the day after drug administration. Twenty-four-hour urinary creatinine was measured as a check on the completeness of collections. stimulation test was performed in six patients before and during EE administration, and in one additional patient no control infusion was performed. For the test, 50 IU of ACTH was given intravenously for exactly 8 hours for 2 successive days, and urinary 17-KGS were measured on both days. An average of 4 days was allowed between the methopyrapone and ACTH tests in each patient.
RESULTS
As can be seen in Table II , the urinary 17-KGS excretion the day after methopyropone administration increased in all eleven patients, with a mean increase of 41.7 mg per 24 hours during the control period. The day after methopyrapone therapy was chosen for tabulation, since urinary 17-KGS were generally highest on this day, although proportionate increases occurred on all days of methopyrapone administration. During EE administration, the mean increase was only 10.9 mg in 24 hours, a value significantly different (p <.02) from the response during the control period. Two The response to ACTH stimulation was studied in seven patients during EE administration, and all responded virtually normally (Table III) . Figures 2 and 3 show the response in two such patients. An ACTH stimulation test was done in Patient 10 twice while she was on EE therapy, and both responses were similar to that of the control period (Figure 3 ). %4ETHOPYRAPO (14) . This elevated level of plasma corticoids depends on an increased plasma level of transcortin (4, 5) . These elevated plasma 17-hydroxycorticoids were presumed to be biologically inactive because estrogen-treated patients presented none of the clinical features of Cushing's syndrome, because with these high plasma levels there was no increase in the glucosuria in diabetic patients (1), and finally, because, by the demonstration of Slaunwhite, Lockie, Back, and Sandberg (15), addition of transcortin to an ini vivo system blocks cortisone effect.
Plasma 17-hydroxycorticosteroids after EE administration have been studied in detail by several workers (3, 6) who showed an augmented response to exogenous ACTH during EE administration in doses of 0.1 mg per day. In addition, Marks, Friedman, and Duncan (16) 2) Inhibition of ACTH secretion. The response of these patients to ACTH stimulation suggests that the estrogen effect is not at the adrenal level, but appears to be in connection with ACTH release from the pituitary. Gemzell's finding (20) of an increase in plasma ACTH in rats treated with estrogen may be secondary to decreased ability of the adrenal to secrete corticoids, known to occur after large doses of estrogen. Vogt (8, 9 ) demonstrated decreased corticosterone secretion in estrogen-treated rats, and similar findings were shown in humans by Peterson and associates (6) , which could have resulted from a decrease in ACTH production, but also could represent decreased ability of the gland to produce corticoids.
3) Increase in CBG acts to suppress ACTH output. Although the studies previously mentioned indicated that corticoids bound to transcortin generally are biologically inactive, the possibility that an increase in circulating concentration of such corticoids during EE treatment could inhibit the release of ACTH from the pituitary should be taken into consideration. On this basis, the decrease in corticosteroid output by the adrenals (6) 
